Nuvalent, Inc. (NUVL)
| Market Cap | 8.32B +57.0% |
| Revenue (ttm) | n/a |
| Net Income | -450.07M |
| EPS | -5.71 |
| Shares Out | 79.00M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 579,883 |
| Open | 103.19 |
| Previous Close | 102.40 |
| Day's Range | 102.26 - 107.52 |
| 52-Week Range | 63.56 - 113.02 |
| Beta | 1.15 |
| Analysts | Strong Buy |
| Price Target | 134.75 (+27.99%) |
| Earnings Date | May 7, 2026 |
About NUVL
Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are Zidesamtinib (NVL-520), a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the Phase 2 portion of... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 16 analysts, the average rating for NUVL stock is "Strong Buy." The 12-month stock price target is $134.75, which is an increase of 27.99% from the latest price.
News
Nuvalent reports Q1 EPS ($1.39), consensus ($1.31)
“The forward momentum continues at Nuvalent (NUVL), with both of our parallel-lead programs advancing toward key US regulatory milestones and the opportunity to bring our first new medicine to patient...
Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2026 Financial Results
NDA submitted for neladalkib in TKI pre-treated advanced ALK-positive NSCLC NDA for zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC under FDA review with PDUFA target action date of Septe...
Guardant Health announces multi-year strategic collaboration with Nuvalent
Guardant Health (GH) announced a multi-year strategic collaboration with Nuvalent (NUVL) to support the development and potential commercialization of Nuvalent’s oncology pipeline using the tissue and...
Guardant Health Announces Multi-Year Strategic Collaboration with Nuvalent to Develop Companion Diagnostics and Support Potential Commercialization of Targeted Cancer Therapies Using the Guardant Infinity™ Platform
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a multi-year strategic collaboration with Nuvalent, Inc. (Nasdaq: NUVL), a...
Nuvalent to Present Pivotal Data from ALKOVE-1 Trial of Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC at the 2026 American Society of Clinical Oncology Annual Meeting
Company to also present preliminary data for zidesamtinib in advanced ROS1-positive solid tumors outside of NSCLC from the global ARROS-1 trial CAMBRIDGE, Mass., April 21, 2026 /PRNewswire/ -- Nuvalen...
Nuvalent to present preclinical data for zidesamtinib at AACR meeting
Nuvalent (NUVL) announced new clinical and preclinical data for zidesamtinib, an investigational ROS1-selective inhibitor, to be presented during poster sessions at the American Association for Cancer...
New Clinical and Preclinical Data for Investigational Candidate Zidesamtinib Presented at AACR Annual Meeting 2026
Zidesamtinib demonstrated meaningful clinical activity in subset of TKI pre-treated ROS1-positive NSCLC patients from ARROS-1 trial previously treated with repotrectinib or taletrectinib, including in...
Nuvalent submits neladalkib NDA to FDA
Nuvalent (NUVL) announced the submission to the FDA of the company’s NDA for neladalkib, an investigational ALK-selective inhibitor, in TKI pre-treated advanced ALK-positive NSCLC. “The advancement of...
Nuvalent Announces Submission of New Drug Application to FDA for Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC
New Drug Application (NDA) based on data in TKI pre-treated patients from the global ALKOVE-1 Phase 1/2 clinical trial CAMBRIDGE, Mass., April 7, 2026 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a ...
Nuvalent initiated with an Overweight at Wells Fargo
Wells Fargo analyst Eva Fortea Verdejo initiated coverage of Nuvalent (NUVL) with an Overweight rating and $116 price target The firm believes the company’s zidesamtinib has “best-in-class” potential ...
Nuvalent to Present New Preclinical and Clinical Data for Zidesamtinib, an Investigational ROS1-Selective Inhibitor, at AACR Annual Meeting 2026
CAMBRIDGE, Mass., March 17, 2026 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase...
Nuvalent Transcript: Leerink Global Healthcare Conference 2026
Significant progress was highlighted across ROS1 and ALK programs, with rapid trial enrollment, strong clinical data showing high response rates and durability, and regulatory milestones positioning both drugs for potential approval and commercial launch. Plans include global commercialization and further pipeline expansion.
Nuvalent Transcript: TD Cowen 46th Annual Health Care Conference
Multiple oncology programs are advancing toward key regulatory milestones in 2024, with strong physician and patient advocacy support driving rapid trial enrollment. Lead assets target significant market opportunities in ALK and ROS1 lung cancer, with commercial readiness and global registration strategies in place.
Nuvalent price target raised to $138 from $132 at UBS
UBS raised the firm’s price target on Nuvalent (NUVL) to $138 from $132 and keeps a Buy rating on the shares.
Nuvalent price target raised to $140 from $135 at Cantor Fitzgerald
Cantor Fitzgerald raised the firm’s price target on Nuvalent (NUVL) to $140 from $135 and keeps an Overweight rating on the shares. With one new drug application under review and
Nuvalent reports Q4 EPS ($1.58), consensus ($1.44)
Cash, cash equivalents and marketable securities were $1.4B as of December 31. Nuvalent (NUVL) continues to believe that its existing cash, cash equivalents and marketable securities will be sufficien...
Nuvalent Outlines Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2025 Financial Results
Commercial preparations well underway to support potential U.S. launch of zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC population, pending FDA review; PDUFA target action date of Septe...
Nuvalent Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
The company is advancing global commercialization of differentiated ROS1 and ALK inhibitors, with US launches expected this year and ex-US expansion underway. Strong clinical data, robust financials, and a growing pipeline—including HER2 and a new candidate—support a vision for sustainable global growth.
Nuvalent to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
CAMBRIDGE, Mass., Feb. 5, 2026 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase t...
Nuvalent Transcript: 44th Annual J.P. Morgan Healthcare Conference
The conference highlighted progress on targeted NSCLC therapies, with pivotal data for zidesamtinib and NVL-655 supporting upcoming FDA submissions and potential approvals. Strong clinical results, commercial readiness, and a robust pipeline position the company for sustainable growth and global expansion.
Nuvalent Announces OnTarget 2026 Operating Plan Progress and Outlines Key Anticipated 2026 Milestones
FDA accepted NDA for zidesamtinib for the treatment of TKI pre-treated patients with advanced ROS1-positive NSCLC; PDUFA target action date of September 18, 2026 NDA submission for neladalkib in TKI p...
Nuvalent files automatic mixed securities shelf
07:52 EST Nuvalent (NUVL) files automatic mixed securities shelf
Nuvalent to Present at the 44th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass. , Dec. 22, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase...
Nuvalent price target lowered to $145 from $147 at JPMorgan
JPMorgan lowered the firm’s price target on Nuvalent (NUVL) to $145 from $147 and keeps an Overweight rating on the shares. The firm updated models in the smid-cap biotechnology group.
Royalty Pharma acquires royalty interest in Nuvalent’s neladalkib, zidesamtinib
Royalty Pharma (RPRX) announced that it has acquired a pre-existing royalty interest in Nuvalent’s (NUVL) neladalkib and zidesamtinib from an undisclosed third party for up to $315 million. Neladalkib...